Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Source: View publication →
The RAPIDO trial demonstrated that a total neoadjuvant therapy (TNT) approach—consisting of short-course radiotherapy followed by systemic chemotherapy—significantly reduces disease-related treatment failure and distant metastases compared to standard preoperative chemoradiotherapy in patients with high-risk locally advanced rectal cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RAPIDO trial establishes total neoadjuvant therapy as a new standard of care for high-risk locally advanced rectal cancer. By shifting chemotherapy to the preoperative setting, this approach achieves higher treatment compliance, higher rates of tumor downstaging (evidenced by increased pCR), and superior control of distant systemic disease compared to the conventional strategy of adjuvant chemotherapy.
Historical Context
Historically, the standard management for locally advanced rectal cancer focused on long-course chemoradiotherapy followed by TME surgery, with adjuvant chemotherapy administered postoperatively to reduce systemic relapse. However, poor adherence to postoperative chemotherapy and the high risk of distant metastases prompted the exploration of total neoadjuvant therapy (TNT) to optimize systemic treatment delivery before surgery.
Guided Discussion
High-yield insights from every perspective
What is the physiological and clinical rationale for using a 'Total Neoadjuvant Therapy' (TNT) approach, as seen in the RAPIDO trial, instead of the traditional sequence of preoperative chemoradiotherapy followed by postoperative adjuvant chemotherapy?
Key Response
TNT aims to deliver all systemic therapy early, when the patient is most fit and compliance is highest. Clinically, this treats micrometastatic disease sooner, increases the likelihood of a pathologic complete response (pCR), and avoids the common delays or omissions of adjuvant chemotherapy that often occur due to postoperative complications or slow recovery from surgery.
Based on the RAPIDO inclusion criteria, which specific MRI-defined 'high-risk' features would lead you to recommend the experimental short-course radiotherapy/chemotherapy protocol over standard long-course chemoradiotherapy?
Key Response
The RAPIDO trial specifically targeted high-risk locally advanced rectal cancer defined by MRI as having at least one of the following: cT4a or cT4b tumors, extramural venous invasion (EMVI+), cN2 stage, involved mesorectal fascia (MRF+), or enlarged lateral lymph nodes. These patients are at higher risk for distant metastasis, making the systemic-first TNT approach particularly beneficial.
Compare the 'Short-Course RT to Chemotherapy' sequence used in RAPIDO with the 'Chemotherapy to Long-Course CRT' sequence used in PRODIGE 23. What are the trade-offs regarding local control and toxicity?
Key Response
RAPIDO used 5x5 Gy followed by CAPOX/FOLFOX, showing excellent systemic control but a slightly higher 5-year local recurrence rate (10% vs 6%). PRODIGE 23 used FOLFIRINOX followed by long-course CRT (50 Gy with capecitabine), which generally provides more potent radiosensitization for local control. Fellows must weigh the convenience and systemic intensity of RAPIDO against the potentially superior local downstaging of long-course-based TNT.
The 5-year follow-up of the RAPIDO trial revealed a higher rate of locoregional recurrence in the experimental TNT group compared to the standard of care. How does this finding influence your multidisciplinary discussion for a patient with a very low rectal tumor where an R0 resection is borderline?
Key Response
The increased local recurrence (10% vs 6%) in the TNT arm suggests that while short-course RT followed by chemotherapy is excellent for preventing distant disease, it may be less effective at ensuring long-term local pelvic control than long-course chemoradiotherapy. In cases where the circumferential resection margin (CRM) is threatened or for very low tumors where sphincter preservation is the goal, an attending might favor long-course CRT to maximize local regression.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The primary endpoint of RAPIDO was 'disease-related treatment failure' (DrTF). Critically evaluate the limitations of using this composite endpoint in a surgical oncology trial where local and distant failure modes have different clinical implications and salvage possibilities.
Key Response
Composite endpoints like DrTF (including local recurrence, metastases, and death) increase statistical power by capturing more events, but they assume that all components are of equal clinical weight. In rectal cancer, a distant metastasis is often terminal, whereas a local recurrence might be surgically salvageable. By grouping them, the trial may mask a treatment that improves one while worsening the other, requiring researchers to carefully deconstruct the components in secondary analyses.
One notable observation in the RAPIDO control arm was that only 58% of patients received the intended adjuvant chemotherapy. To what extent does this 'pragmatic' failure of the control arm jeopardize the internal validity of the trial's conclusion regarding the superiority of TNT?
Key Response
A tough reviewer would argue that the trial compares TNT not just to 'standard timing,' but to an 'under-treated' control group. If the benefit of TNT is merely that patients actually received the chemotherapy they were supposed to get, the study proves the logistical superiority of neoadjuvant delivery rather than a biological advantage of the timing itself. This highlights the difficulty of executing 'standard' adjuvant arms in modern colorectal trials.
Given the results of RAPIDO and the PRODIGE 23 trials, how should current guidelines (such as NCCN or ESMO) be updated regarding the 'Level of Evidence' for TNT in high-risk LARC, and should short-course RT-based TNT be preferred over long-course-based TNT?
Key Response
Both RAPIDO and PRODIGE 23 provide Category 1/Level 1a evidence for TNT as a standard of care for high-risk LARC. However, guidelines must remain nuanced; the NCCN already lists both as options. The committee must decide whether to issue a 'preference' based on the 5-year local recurrence data from RAPIDO, potentially recommending long-course CRT-based TNT (PRODIGE 23 style) for patients where local control is the primary concern (e.g., MRF+ or low tumors).
Clinical Landscape
Noteworthy Related Trials
CAO/ARO/AIO-94 Trial
Tested
Preoperative chemoradiotherapy (5-FU based)
Population
Patients with clinical T3 or T4 rectal cancer
Comparator
Postoperative chemoradiotherapy
Endpoint
Disease-free survival
Polish II Trial
Tested
Preoperative chemoradiotherapy (oxaliplatin/5-FU)
Population
Patients with clinical T3 or T4 rectal cancer
Comparator
Preoperative radiotherapy alone
Endpoint
3-year disease-free survival
PRODIGE 23 Trial
Tested
Neoadjuvant FOLFIRINOX followed by chemoradiotherapy and TME
Population
Patients with locally advanced rectal cancer
Comparator
Standard preoperative chemoradiotherapy and TME
Endpoint
Disease-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis